Notably, a recent phase 2 clinical study demonstrated that ponsegromab, an anti‐GDF15 antibody, induced weight gain, improved physical activity and reduced cachexia symptoms in patients with cancer cachexia, confirming GDF15's role as a key driver of cachexia (Supporting Information: Reference S26). The gene discussed is GDF15; the disease is cancer.